|
| 37523551 | Activin E-ACVR1C cross talk controls energy storage via suppression of adipose lipolysis in mice. | | 2023 |
| 37992152 | Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency. | | 2023 |
| 38091405 | A therapeutic strategy to target distinct sources of IgE and durably reverse allergy. | | 2023 |
| 37792612 | Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. | N Engl J Med | 2023 |
| 37613478 | Structural Analysis of Cancer-relevant TCR-CD3 and Peptide-MHC Complexes by CryoEM. | | 2023 |
| 37770652 | Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. | Nat Med | 2023 |
| 37410813 | A cellular and molecular spatial atlas of dystrophic muscle. | | 2023 |
| 37272521 | Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. | | 2023 |
| 37142763 | Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. | Nat Med | 2023 |
| 36494054 | Association of complement pathways with COVID-19 severity and outcomes. | Microbes Infect | 2023 |
| 36481478 | IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline. | | 2023 |
| 36630481 | Blocking common γ chain cytokine signaling ameliorates T cell-mediated pathogenesis in disease models. | Sci Transl Med | 2023 |
| 36930708 | Structural insights into the assembly of gp130 family cytokine signaling complexes. | | 2023 |
| 37100770 | Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM. | | 2023 |
| 35139273 | Survival with Cemiplimab in Recurrent Cervical Cancer. | N Engl J Med | 2022 |
| 35969402 | Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial. | JAMA Netw Open | 2022 |
| 35895508 | Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19. | J Infect Dis | 2022 |
| 36008722 | Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. | Nature Medicine | 2022 |
| 36001963 | Disruption of nuclear envelope integrity as a possible initiating event in tauopathies. | Cell Reports | 2022 |
| 35999217 | Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. | Nat Commun | 2022 |
| 35939579 | Germline Mutations in <i>CIDEB</i> and Protection against Liver Disease. | N Engl J Med | 2022 |
| 35934082 | REGN1908/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit. | Journal of Allergy and Clinical Immunology | 2022 |
| 35788416 | Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19. | Int J Infect Dis | 2022 |
| 36255239 | Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies. | mBio | 2022 |
| 36546624 | Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. | N Engl J Med | 2022 |
| 34126156 | Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study. | Journal of Allergy and Clinical Immunology | 2022 |
| 34126155 | Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response. | Journal of Allergy and Clinical Immunology | 2022 |
| 33507266 | Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus. | J Infect Dis | 2022 |
| 35219277 | Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial. | Clin Infect Dis | 2022 |
| 35029629 | Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. | JAMA | 2022 |
| 34971385 | Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders. | Clinical Infectious Diseases | 2022 |
| 34587383 | REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. | N Engl J Med | 2021 |
| 33581821 | Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. | Lancet, The | 2021 |
| 34161776 | The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. | Cell | 2021 |
| 34159343 | Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. | | 2021 |
| 34000246 | Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. | Lancet Oncol | 2021 |
| 34210852 | Sequencing of 640,000 exomes identifies <i>GPR75</i> variants associated with protection from obesity. | Science | 2021 |
| 33651675 | Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. | American Journal of Respiratory and Critical Care Medicine | 2021 |
| 34347950 | Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. | New England Journal of Medicine | 2021 |
| 34302758 | Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. | Lancet Respiratory Medicine,The | 2021 |
| 34351414 | Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. | JAMA Ophthalmology | 2021 |
| 33199274 | Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial. | Annals of the Rheumatic Diseases | 2021 |
| 33288630 | Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy. | Journal of the American Society of Nephrology : JASN | 2021 |
| 33332778 | REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. | N Engl J Med | 2021 |
| 32897368 | Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. | Clin Infect Dis | 2021 |
| 34919442 | Humanization of T cell-mediated immunity in mice. | Science immunology | 2021 |
| 34662886 | Exome sequencing and analysis of 454,787 UK Biobank participants. | Nature | 2021 |
| 34706171 | Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. | New England Journal of Medicine | 2021 |
| 34879449 | Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. | N Engl J Med | 2021 |
| 32574587 | Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11Â years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. | J Am Acad Dermatol | 2020 |